Amazon has announced it will cease the sale of seven brands of eyedrops following a warning from the U.S. Food and Drug Administration (FDA). The FDA’s letter to Amazon’s CEO, Andrew Jassy, highlighted that these products were being sold as “unapproved new drugs” on the platform, violating federal regulations.
The FDA’s concerns stem from the potential health risks posed by these eyedrops, which include claims to treat conditions such as pink eye, dry eyes, and eyestrain. The products in question are Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, TRP Natural Eyes Floaters Relief, and Manzanilla Sophia Chamomile Herbal Eye Drops.
In response, an Amazon spokesperson emphasized the company’s commitment to safety, stating that all products sold must comply with applicable laws and regulations. The spokesperson confirmed that the products are being removed from the site.
The FDA’s letter underscored the heightened risk associated with ophthalmic drug products, as they bypass some of the body’s natural defenses. The agency also noted that these products are not generally recognized as safe and effective for their intended uses, classifying them as “new drugs” under the Federal Food, Drug, and Cosmetic Act.
This eyedrops recall reflects the ongoing efforts to ensure consumer safety and compliance with federal health regulations.